OrthopaedicsTechnology

Biologics in Spine Surgery

PatrickDriscoll
2 Min Read
mHealth Patient Care

Successful bone fusion requires three critical elements: an osteogenic potential capable of directly providing cells to the newly forming bone, osteoinductive factors that can cause osteoprogenitor stem cells to differentiate into osteoblasts, and an osteoconductive scaffold that facilitates neovascularization and supports the ingrowth of bone.

Successful bone fusion requires three critical elements: an osteogenic potential capable of directly providing cells to the newly forming bone, osteoinductive factors that can cause osteoprogenitor stem cells to differentiate into osteoblasts, and an osteoconductive scaffold that facilitates neovascularization and supports the ingrowth of bone.

While autograft has traditionally been the material of choice for spinal fusion, there has been an unacceptably high rate of pseudoarthrosis has been reported in the literature, ranging from 5-43%. This has helped to drive development of new and improved procedures and new devices intended to improve the rate of successful spinal fusion, but symptomatic pseudoarthrosis has continued to be reported at rates of 10-15%. In addition, the frequent incidence of pain at the site of the bone graft harvest has always been a serious drawback to the use of autograft for spinal fusion. Problems such as these have caused surgeons and companies to search for novel biological strategies and materials that may serve as alternatives to autograft, to stimulate strong and successful bone fusion.

[Inset: DePuy Vertigraft]

More Read

Exploring the Top 10 Trends in Medical Alert Systems

Best Practices for Healthcare UX Design
5 Key Considerations in Packaging and Shipping Medical Devices
Can Healthcare Analytics Really Trim Down Your Bills? Let’s Discover Some Valuable Insights
10 Benefits of Using Asset Management Software in the Healthcare Industry

A number of companies are working in the Biologics space, not only marketing present products but also developing novel proprietary products. Among the interesting developments worth watching are new technologies for bone and disc regeneration, and advances in gene therapy and in osteoinductive proteins and carrier matrices, and mesenchymal stem cells.

See the MedMarket Diligence report #M520 for details (interim report available).

     

TAGGED:
Share This Article
By PatrickDriscoll
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses. Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Previous Article Smart Phone Device Takes EKGs in 30 seconds
Next Article Ventura County Operation Medical Shelter
Exit mobile version